Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Articles

Chris Spivey, editorial director for Pharmaceutical Technology, discusses messenger RNA (mRNA) advances with Guillaume Roelandts, Head of Products and Marketing, Quantoom Biosciences, at the 11th International mRNA Health Conference in Berlin, Germany.

Tackling Production Challenges through Greater Access to mRNA Technologies

Feliza Mirasol is the science editor for 

MilliporeSigma has expanded its biosafety testing laboratories in Shanghai, China, with the completion of new lab space at its new €29 million (US$43 million) Biologics Testing Center.

MilliporeSigma Expands Biologics Testing Center in China

Looking at the role that RSV and pediatric medical practices play in drug shortages.

Why We Were Not Properly Winterized for RSV Season

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The largest biotech hub is set to be built in Lithuania by Northway Group.

Lithuania Set to Become Home to Largest Biotech City

Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.

Hovione Expands Technology Platforms with ExtremoChem Acquisition

Chris Spivey, editorial director for Pharmaceutical Technology and Biopharm International, spoke with Concetto Andrea Rizza, Marketing and Communications manager, ICE Pharma, on sustainability and ICE’s green approach at CPhI Barcelona 2023.

Centering Sustainability and Environmental Impact in the Supply Chain

UK industry body, ABPI, has responded positively to the recent Autumn Statement.

Industry Responds to the UK’s Autumn Statement

PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, at the 11th International mRNA Health Conference in Berlin, Germany.

Democratizing GMP Manufacturing for the New Therapeutic Pipeline

In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part Two)

Consent decrees were issued against Evig LLC, of St. George, Utah, and Premium Production LLC, of St. George, Utah, for unapproved dietary supplements.

News